1 Oral: First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation
Titel:
1 Oral: First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation
Auteur:
Yap, T.A. Dowlati, A. Dagogo-Jack, I. Vibert, J. Spira, A.I. Garcia, V. Moreno Punekar, S.R. Calvo, E. Sonpavde, G.P. Awad, M. Riess, J.W. Hernández-Guerrero, T. Herzberg, B. Italiano, A. Swalduz, A. LoRusso, P. Smit, E.F. Garon, E.B. Novotny, W. Guo, R.